We are live on
!
Find out more
IDXG
Interpace Biosciences, Inc. Common Stock
IDXG
IDXG
Delisted
IDXG was delisted on the 24th of February, 2021.
18 hedge funds and large institutions have $7.02M invested in Interpace Biosciences, Inc. Common Stock in 2018 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 8 closing their positions.
New
Increased
Maintained
Reduced
Closed
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
125% more capital invested
Capital invested by funds: $3.12M → $7.02M (+$3.9M)
13% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 8
6% more funds holding
Funds holding: 17 → 18 (+1)
Holders
18
Holders Change
+1
Holders Change %
+5.88%
% of All Funds
0.41%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
4
Reduced
1
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
SSA
Schonfeld Strategic Advisors
New York
|
+$934K |
| 2 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
+$769K |
| 3 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
+$364K |
| 4 |
JP Morgan Chase
New York
|
+$151K |
| 5 |
VF
Virtu Financial
New York
|
+$90.6K |
